Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976869 | 0.86 | SLC22A12 (0.63) | SLC22A12ACHEALDH1A1MAPTTSHR | |
| SCHEMBL11975007 | 0.82 | SLC22A12 (1.00) | SLC22A12ACHEMAPTHDAC1HDAC6 | |
| SCHEMBL6177893 | 0.81 | ACHE (0.63) | SLC22A12ACHEALDH1A1MAPTHDAC1 | |
| SCHEMBL5404613 | 0.79 | ACHE (0.46) | SLC22A12ACHEALDH1A1MAPTMYC | |
| Potassium Ion SCHEMBL15400487 | 0.79 | SLC22A12 (0.80) | SLC22A12ACHEHDAC1HDAC6 | |
| SCHEMBL11977154 | 0.77 | SLC22A12 (0.77) | SLC22A12ALDH1A1MAPTTSHRGAA | |
| SCHEMBL11975009 | 0.75 | SLC22A12 (0.67) | SLC22A12TSHRHDAC1HDAC6 | |
| SCHEMBL3349545 | 0.75 | ACHE (0.47) | SLC22A12ACHEALDH1A1MAPTGAA | |
| SCHEMBL28447449 | 0.74 | MEN1 (0.46) | SLC22A12ACHEALDH1A1MAPTMYC | |
| SCHEMBL5134560 | 0.73 | LMNA (0.50) | ACHEHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| WO-2012102405-A1 | RING-FUSED COMPOUND | 佐藤製薬株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | SLC22A12 394/4885ACHE 3840/4885ALDH1A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.